Immunic director granted 25,370 stock options

IMMUNIC, INC. director Simona Skerjanec received a grant of stock options covering 25,370 shares of common stock.

Rhea-AI Filing Summary

IMMUNIC, INC. director Simona Skerjanec received a grant of stock options covering 25,370 shares of common stock. The options carry an exercise price of $10.90 per share and are fully vested as of March 27, 2026. The grant was conditionally approved by the board on March 27, 2026 and became effective after stockholders approved an amendment to the company’s 2019 Omnibus Equity Incentive Plan at the 2026 Annual Meeting held on June 29, 2026. Following this grant, Skerjanec holds 25,370 stock options directly.

Insider Trade Summary

Grant/Award: 25,370 shares

Grant/Award 1 txn

Insider Skerjanec Simona

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	25,370	$0.00	$0.00

Holdings After Transaction: Stock Option — 25,370 contracts (Direct)

Footnotes (2)

1. F1. Represents options to purchase shares of common stock conditionally approved by the Board of Directors on March 27, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026.
2. F2. The option is fully vested as of March 27, 2026.

Key Figures

Options granted: 25,370 options Exercise price: $10.90 per share Total options after grant: 25,370 options +2 more

5 metrics

Options granted 25,370 options Stock option grant to director Simona Skerjanec

Exercise price $10.90 per share Stock option exercise price

Total options after grant 25,370 options Total derivative holdings following transaction

Option expiration date March 27, 2036 Final exercise date for granted options

Vesting date March 27, 2026 Options fully vested as of this date

Key Terms

Stock Option, 2019 Omnibus Equity Incentive Plan, Annual Meeting of Stockholders, exercise price

4 terms

Stock Option financial

"security_title: Stock Option with underlying Immunic common stock"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

2019 Omnibus Equity Incentive Plan financial

"subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended"

Annual Meeting of Stockholders financial

"approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026"

exercise price financial

"conversion_or_exercise_price: 10.9000 per share for the stock options"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Immunic (IMUX) director Simona Skerjanec receive in this Form 4?

Director Simona Skerjanec received a grant of stock options for 25,370 shares of Immunic common stock. These options represent equity-based compensation and give her the right to buy shares at a fixed exercise price in the future.

What is the exercise price of the Immunic (IMUX) stock options granted to Simona Skerjanec?

The options were granted with a $10.90 per share exercise price. This means Skerjanec can purchase Immunic common stock at $10.90 per share under the option terms, regardless of the market price when she chooses to exercise.

When do Simona Skerjanec’s Immunic (IMUX) stock options vest and expire?

The stock options are fully vested as of March 27, 2026, so no additional service is required. The options expire on March 27, 2036, providing a 10-year window from the vesting date to exercise the right to purchase shares.

Were Immunic (IMUX) shareholders involved in approving this stock option grant?

Yes. The board conditionally approved the options on March 27, 2026, subject to stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan, which shareholders granted at the 2026 Annual Meeting on June 29, 2026.

How many Immunic (IMUX) stock options does Simona Skerjanec hold after this transaction?

After this grant, Skerjanec directly holds 25,370 stock options. Each option entitles her to purchase one share of Immunic common stock, so the position currently corresponds to 25,370 underlying shares if fully exercised.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Skerjanec Simona

(Last) (First) (Middle)

1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$10.9	06/29/2026		A		25,370(1)		(2)	03/27/2036	Common Stock	25,370	$0.00	25,370	D

Explanation of Responses:

1. Represents options to purchase shares of common stock conditionally approved by the Board of Directors on March 27, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026.

2. The option is fully vested as of March 27, 2026.

	/s/ Simona Skerjanec	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)